Goldman Sachs reiterates a "Buy" rating for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), indicating confidence in the company's growth potential.The stock price of Madrigal Pharmaceuticals experienced a decrease of 3.26%, showing market volatility.Madrigal's presentation at the 44th Annual J.P. Morgan Healthcare Conference highlights its strategic direction and developments in the NASH space.Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on developing innovative therapi ...